Bernie Sunwoo, MD
Pulmonary Disease · San Diego, CANPI 1336294107
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Eisai Inc. accounts for 62.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 2 payments — averaging $99.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$125
- Philips North America LLC$74
Across 6 payments — averaging $35,436 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$213K
What the payments were for
- Food & beverage$199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 1 | $125 |
| Philips North America LLC | 1 | $74 |
How this compares
$199 in reported general payments places this provider in the 25th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 25 | $276,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $55,733 |
| Spiriva RespimatTiotropium Bromide | 74 | $47,665 |
| Dupixent PenDupilumab | 11 | $37,849 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $21,809 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $19,039 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $13,554 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $13,230 |
| DuleraMometasone/Formoterol | 29 | $11,355 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,864 |
| Fluticasone Propionate HfaFluticasone Propionate | 16 | $5,059 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $4,909 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $4,297 |
| Sirolimus | 12 | $3,766 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,997 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in San Diego
- George ChengSan Diego$291K
- Samir MakaniSan Diego$179K
- Shari BrazinskySan Diego$82K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.